OSAKA, Japan & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ ...

Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout By Nick Paul Taylor Jun 27, 2025 9:00am Turnstone Biologics Xoma mergers and acquisitions Oncology ...

Takeda Ireland has received the award for overall excellence in life sciences at the Life Sciences Industry Awards 2025, the annual event that celebrates the most innovative individuals and ...

TAK Company Profile Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

Takeda-backed INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

View the latest Takeda Pharmaceutical Co. Ltd. ADR (TAK) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Protagonist Therapeutics, Inc.Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy ...